Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer
Open accessThe DOI matches its Crossref record; 41 of the 44 references it cites were found in a registry or an index.
Abstract
Background We evaluated AMG 386, an investigational peptibody that neutralizes the interaction between angiopoietins-1 and -2 and the Tie2 receptor, combined with cisplatin/capecitabine (CX) as first-line treatment for metastatic gastro-oesophageal cancer.Patients and methods Patients with metastatic gastric, gastro-oesophageal junction, or distal oesophageal adenocarcinoma were randomized 1:1:1 to CX (cisplatin 80 mg/m(2) IV Q3W; capecitabine 1000 mg/m(2) P.O. BID for 14 days Q3W) plus intravenous AMG 386 10 mg/kg QW (Arm A) or 3 mg/kg QW (Arm B), or placebo QW (Arm C). The primary end point was estimated progression-free survival (PFS).Results A total of 171 patients were enrolled. Median estimated PFS in Arms A, B, and C was 4.2, 4.9, and 5.2 months, respectively (hazard ratio for Arms A+B combined versus Arm C, 0.98; 95% CI 0.67-1.43; P = 0.92). Objective response rates were 27% (Arm A), 43% (Arm B), and 35% (Arm C). Incidence of grade ≥3 adverse events was 80% in Arm A, 84% in Arm B, and 75% in Arm C. There was no evidence of pharmacokinetic interactions.Conclusions In this study, PFS and ORR were estimated to be similar with AMG 386 plus CX and placebo plus CX treatment. Compared with placebo, toxicity of AMG 386 plus CX was greater but manageable.Previous presentation The results of this study have not been previously published or submitted for publication elsewhere. The results were presented in part at the Gastrointestinal Cancers Symposium, San Francisco, CA, January 20-22, 2011.Clinical trial registration ClinicalTrials.gov registration number: NCT00583674.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the results of clinical studies targeting both ANG1 and ANG2 using the bi-specific peptibody trebananib have been disappointing.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggests that the vessel-normalizing effects of ANG1–ANG2 blockade are generally insufficient to improve patient outcomes.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [84]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the addition of trebananib to cisplatin and capecitabine chemotherapy failed to prolong the estimated median PFS duration in patients with metastatic gastroesophageal cancer (HR 0.98, 95% CI 0.67–1.43; P = 0.92) in a randomized, double-blind, placebo-controlled phase II study84.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20006 · Cited by 9,709
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302 · cited 3×
“Decreased appetite 17 (30) 5 (9) 31 (53) 5 (9) 23 (43) 3 (6)”
Kamangar, F., Dores, G. M., & Anderson, W. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2308 · Cited by 3,434 · cited 1×
“Gastric cancer is the fourth most common malignancy worldwide [1, 2].”
BackgroundModelling for Survival Data in Medical Research
(1995) · Technometrics · doi:10.1080/00401706.1995.10485920 · Cited by 2,145
Interval estimation for the difference between independent proportions: comparison of eleven methods
Newcombe, R. G. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19980430)17:8<873::aid-sim779>3.0.co;2-i · Cited by 1,851 · cited 1×
“Wilson’s score method with continuity correction was used to calculate 95% CIs for differences in ORR between treatment arms [31].”
MethodGastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Okines, A., Verheij, M., Allum, W., Cunningham, D., & Cervantes, A. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq164 · Cited by 1,300
Ohtsu, A., Shah, M. A., Van Cutsem, E., Rha, S. Y., Sawaki, A., Park, S. R., Lim, H. Y., Yamada, Y., Wu, J., Langer, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.2236 · Cited by 1,110
Gale, N. W., Thurston, G., Hackett, S. F., Renard, R., Wang, Q., McClain, J., Martin, C., Witte, C., Witte, M. H., Jackson, D., et al. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00217-4 · Cited by 1,018
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Research works printed but not linked: 1
- Okugawa Y, Miki C, Toiyama Y et al.. Serum soluble VCAM-1 as a valuable prognostic marker in colorectal carcinoma [abstract]. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA, 2008.
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Drugs derived from phage display: From candidate identification to clinical practice
Nixon, A. E., Sexton, D. J., & Ladner, R. C. (2014) · mAbs · doi:10.4161/mabs.27240 · Cited by 167
Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer
Janmaat, V. T., Steyerberg, E. W., van der Gaast, A., Mathijssen, R. H. J., Bruno, M. J., Peppelenbosch, M. P., Kuipers, E. J., & Spaander, M. C. W. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004063.pub4 · Cited by 151
Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies
Quail, D. F., & Joyce, J. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0133 · Cited by 135
Vascular Normalization: A New Window Opened for Cancer Therapies
Yang, T., Xiao, H., Liu, X., Wang, Z., Zhang, Q., Wei, N., & Guo, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719836 · Cited by 141
Metadata
- Authors
- Eatock, M. M., Tebbutt, N. C., Bampton, C. L., Strickland, A. H., Valladares-Ayerbes, M., Swieboda-Sadlej, A., Van Cutsem, E., Nanayakkara, N., Sun, Y.-N., Zhong, Z. D., Bass, M. B., Adewoye, A. H., & Bodoky, G.
- Affiliations
- Belfast City Hospital (GB)
- Northern Health (AU)
- Monash Medical Centre (AU)
- IQVIA (United States) (US)
- Amgen (United States) (US)
- Unified Szent István and Szent László Hospital (HU)
- Corresponding author
- Eatock, M.M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2013-03
- Volume
- 24
- Issue
- 3
- Pages
- 710-718
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2061877116
- Cited by
- 64
- References
- 44
- Citations by year
- 2025: 3 · 2024: 1 · 2023: 5 · 2022: 4 · 2021: 7 · 2019: 5 · 2018: 4 · 2017: 7 · 2016: 3 · 2015: 8 · 2014: 8 · 2013: 8
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 2503 d)
- Locations
- Annals of Oncology (publishedVersion)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Funders
- Amgen Inc
- Topics
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- trebananib, angiopoietin-2, angiopoietin-1, Tie2 receptor, peptibody, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, cisplatin, capecitabine, first-line therapy, progression-free survival, objective response rate, adverse events
- MeSH terms
- Capecitabine, Adenocarcinoma, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cardiovascular Diseases, Cisplatin, Deoxycytidine, Double-Blind Method, Esophageal Neoplasms, Female, Fluorouracil, Humans, Male, Middle Aged, Recombinant Fusion Proteins, Stomach Neoplasms, Treatment Outcome, Disease-Free Survival, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. https://app.cochat.ai/papers/10.1093/annonc/mds502
- The paper
- Eatock, M. M., Tebbutt, N. C., Bampton, C. L., Strickland, A. H., Valladares-Ayerbes, M., Swieboda-Sadlej, A., Van Cutsem, E., Nanayakkara, N., Sun, Y.-N., Zhong, Z. D., Bass, M. B., Adewoye, A. H., & Bodoky, G. (2013). Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. Annals of Oncology. https://doi.org/10.1093/annonc/mds502
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.